



Company Regn No: 200004639G

FOR IMMEDIATE RELEASE

S*BIO Appoints Ms Tamar Howson as Interim Chief Executive Officer

--20-Year Industry Veteran Brings Extensive Healthcare Experience and Proven Track Record in Life Science Partnering & Licensing--

SINGAPORE, September 16, 2011 - S*BIO Pte Ltd today announced that Ms Tamar Howson has been appointed Interim Chief Executive Officer, effective September 16, 2011.

This appointment comes as S*BIO undertakes an internal restructuring to move from a research-focused to a product-focused entity.

Ms Howson, a S*BIO Board Director since 2009, has over 20 years of experience in life science partnering and licensing, having served in senior leadership positions at SmithKline Beecham (now GSK), Bristol-Myers Squibb, Lexicon Pharmaceuticals and venture funds Johnston Associates and SR One.

Dr Jan-Anders Karlsson has resigned as CEO to pursue his personal interests. Under his leadership, Dr. Karlsson has made significant contributions in transforming S*BIO from a research focused to a clinical development stage company with its lead JAK2 inhibitor pacritinib (SB1518) ready for phase 3 studies.

In her role as Interim CEO, Ms Howson will lead S*BIO and progress the lead JAK2 program towards product commercialisation. Ms Howson has worked extensively with both large pharmaceutical and commercial stage biotechnology companies. She currently also serves on the boards of Idenix Pharmaceuticals, Aradigm, Soligenix and OXiGENE, and was previously on the boards of Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept and BiolineRx.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around kinases and histone deacetylases (HDAC). SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has now completed Phase 2 trials for MF. It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, SB939, is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a



Company Regn No: 200004639G

worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. More information about S*BIO can be found at www.sbio.com.

S*BIO Pte Ltd:

Hew Yin Chin, Ph.D.
Director, Corporate Development
Tel: +65 6827 5000 (Singapore)
yinchin_hew@sbio.com

Russo Partners:

Tony Russo +1 212-845-4251
Tony.Russo@russopartnersllc.com
Andreas Marathovouniotis +1 212-845-4235
Andreas.Marathis@russopartnersllc.com